tony sav retweeted
🍄 $OPTH | Optimi Health has completed production and quality release of a new batch of its 5mg naturally derived psilocybin capsules, manufactured through the company’s in-house cGMP operations.
What makes this batch particularly notable is where it’s going.
The same product is being supplied for a Health Canada-authorized Phase 2 study in Major Depressive Disorder, expected to enroll up to 200 patients, while also supporting commercial supply to authorized clinics in Australia treating patients with treatment-resistant depression.
That creates an interesting overlap between Optimi’s clinical development and existing commercial operations. Manufacturing, encapsulation and quality release are being handled internally, giving the company control over more of the pharmaceutical supply chain as these programs advance.
Alongside the production update, $OPTH appointed Melanie Pump to its Board of Directors. Pump brings more than 25 years of financial leadership experience across technology, digital infrastructure, software, fintech and emerging-growth companies.
Taken together, the recent developments show Optimi continuing to build across multiple parts of the business at once — clinical development, regulated commercial supply, in-house manufacturing and corporate leadership.
The next thing worth following is how that infrastructure translates as the Phase 2 program progresses and commercial distribution expands.
Communicated Disclaimer - stockresearchtoday.com/opth/
tony sav retweeted
$OPTH STRENGTHENS ITS BOARD WITH 25+ YEARS OF FINANCIAL LEADERSHIP
Optimi Health $OPTH has appointed seasoned finance executive Melanie Pump to its Board of Directors as the company continues expanding its regulated psychedelic pharmaceutical business.
Pump brings 25+ years of experience across:
▫️ Finance & corporate strategy
▫️ Technology + digital infrastructure
▫️ Fintech & software
▫️ Emerging-growth companies
▫️ Public-company governance
She currently serves as CFO of Qu Data Centres and sits on the Board of Mobio Technologies $MBO, with previous board experience at BTCS.
WHY IT MATTERS 👀
This appointment adds deeper financial and public-market experience at a time when Optimi is moving beyond development and building out its commercial footprint.
$OPTH already manufactures GMP-grade MDMA + botanical psilocybin, with products being supplied to regulated clinical and therapeutic programs internationally, including patient access in Australia and Canada.
Another experienced addition to the leadership table as Optimi works to scale its position in regulated psychedelics. 🍄
tony sav retweeted
We have responded to your query over DM and will continue to assist you over there.
tony sav retweeted
giving away $50 to 10 people who are:
following me on fomo (drop screenshot)
max engage + tag 2 people
drop wallets picking winner soon fomo.family/profile/fyotrade…
tony sav retweeted
gm.
A question I keep getting: why will everything be gated behind $PURRS?
Because a token that does nothing is worth nothing, and most of them do nothing.
So here's the rule. Every action in the management layer will cost $PURRS, and every $PURRS spent gets burned. Not moved to a treasury. Not locked in a contract I control. Gone.
That means the token isn't a ticket to hold and hope. It's the thing you spend to use what you own. And the more people use it, the less of it exists.
I could have charged in ETH and kept it. That would have been better for me and worse for you.
This way the only people who benefit from the product working are the people already holding it.
